Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura™ in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had “no concerns regarding safety of the data to date, and voted that the study continue without modification to the protocol or charter.”

This follows six positive reviews by a separate independent blisibimod DSMB for the CHABLIS-SC1 clinical study in patients with lupus and the BRIGHT-SC clinical study in patients with IgA nephropathy that recommended that the studies continue without modification, with the latest positive review occurring in June of this year. (Original Source)

Shares of Anthera jumped over 11% to $3.54 in pre-market trading. ANTH has a 1-year high of $10 and a 1-year low of $2.28. The stock’s 50-day moving average is $3.19 and its 200-day moving average is $3.40.

On the ratings front, Anthera has been the subject of a number of recent research reports. In a report issued on August 9, Jefferies Co. analyst Eun Yang reiterated a Buy rating on ANTH. Separately, on July 8, H.C. Wainwright’s Andrew Fein initiated coverage with a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eun Yang and Andrew Fein have a total average return of -1.0% and 14.8% respectively. Yang has a success rate of 57% and is ranked #3137 out of 4121 analysts, while Fein has a success rate of 49% and is ranked #182.

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. It develops phase 3 product candidates, which includes blisibimod and liprotamase.